Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, 2x2 Cross-over Euglycemic Clamp Study in Two Parallel Cohorts to Compare the Pharmacodynamic and Pharmacokinetic Properties of 0.4 and 0.6 U/kg/day Insulin Glargine (Toujeo) with the Same Dose Levels of Insulin Degludec (Tresiba) in Steady State After 8 Days Multiple Dosing Regimen in Patients with Diabetes Mellitus Type 1

Next Previous
Trial Profile

A Randomized, Double-blind, 2x2 Cross-over Euglycemic Clamp Study in Two Parallel Cohorts to Compare the Pharmacodynamic and Pharmacokinetic Properties of 0.4 and 0.6 U/kg/day Insulin Glargine (Toujeo) with the Same Dose Levels of Insulin Degludec (Tresiba) in Steady State After 8 Days Multiple Dosing Regimen in Patients with Diabetes Mellitus Type 1

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Oct 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin degludec
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Sanofi

Most Recent Events

  • 11 Nov 2016 Results published in a Sanofi media release.
  • 12 Oct 2016 Status changed from recruiting to completed.
  • 15 Sep 2016 Results published in the Sanofi Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top